Bellicum Pharmaceuticals, Inc.
BLCM
BLCM was delisted on the 1st of June, 2023.
33 hedge funds and large institutions have $1.23M invested in Bellicum Pharmaceuticals, Inc. in 2022 Q4 according to their latest regulatory filings, with 7 funds opening new positions, 4 increasing their positions, 5 reducing their positions, and 1 closing their positions.
600% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 1
18% more funds holding
Funds holding: 28 → 33 (+5)
20% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 5
42% less capital invested
Capital invested by funds: $2.13M → $1.23M (-$900K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HF
HRT Financial
New York
|
+$36.1K |
| 2 |
Millennium Management
New York
|
+$21.4K |
| 3 |
E
Ergoteles
New York
|
+$17.9K |
| 4 |
Jane Street
New York
|
+$16.2K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$12.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$181K |
| 2 |
BlackRock
New York
|
-$183 |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
-$153 |
| 4 |
Osaic Holdings
Scottsdale,
Arizona
|
-$99 |
| 5 |
TC
Truvestments Capital
Sarasota,
Florida
|
-$17 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
OCM
26
Orion Capital Management
Coronado,
California
| $360 | – | – | – |
|
|
MCC
27
Money Concepts Capital
Palm Beach Gardens,
Florida
| $190 | +$261 | +264 | New |
|
|
TC
28
Truvestments Capital
Sarasota,
Florida
| $30 | -$17 | -17 | -29% |
|
|
PA
29
Parallel Advisors
San Francisco,
California
| $7 | – | – | – |
|
|
NSIM
30
North Star Investment Management
Chicago,
Illinois
| $1 | – | – | – |
|
31
JP Morgan Chase
New York
| – | +$1 | +1 | New |
|
BLCM Hedge Fund Activity: Q4 2022 in Review
33 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Bellicum Pharmaceuticals, Inc. (BLCM) for Q4 2022, worth a combined $1.23M — down 42% from $2.13M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new BLCM positions and 1 closed out — a net gain of 6 holders — while 4 added to existing stakes and 5 trimmed.
The largest buyer was HRT Financial, opening a new position worth an estimated $36.1K. The largest seller was Vanguard Group, cutting an estimated $181K.
- 33 institutional investors held Bellicum Pharmaceuticals, Inc. (BLCM) as of Q4 2022, up from 28 in Q3 2022.
- Funds reported $1.23M of Bellicum Pharmaceuticals, Inc. stock for Q4 2022, down 42% quarter-over-quarter.
- 7 funds opened new Bellicum Pharmaceuticals, Inc. positions in Q4 2022 and 1 closed out, a net change of +6 holders.
- The largest Bellicum Pharmaceuticals, Inc. buyer in Q4 2022 was HRT Financial, an estimated $36.1K added.
- The largest Bellicum Pharmaceuticals, Inc. seller in Q4 2022 was Vanguard Group, an estimated $181K sold.
Based on aggregated 13F filings for Q4 2022.